MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia
Fiona C. Brown(Memorial Sloan Kettering Cancer Center), Alex Kentsis(Memorial Sloan Kettering Cancer Center)
Cited by 8
Related Papers
Peptidomimetic blockade of MYB in acute myeloid leukemia
|Nature Communications|2018|95
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor
|JCI Insight|2019|29
Peptidomimetic blockade of MYB in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2017|11
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
|Journal of Clinical Investigation|2025|4
Forward genetic screen of human transposase genomic rearrangements
|bioRxiv (Cold Spring Harbor Laboratory)|2016|0